Internal Medicine · Plantation, FL
NPI
1356305601
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
300 NW 70th Ave, Ste 105
Plantation, FL, 33317
Phone (954) 585-6292
Groups this clinician bills Medicare through
Medicare paid, 2024
$139K
1,617 services
Medicare patients, 2024
437
Average age 74
Drug cost, 2024
$3.9M
10,713 prescriptions
Company payments, 2025
$13K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mudit Jain was code 99214 (office e&m - established), 844 times for 341 patients. In total Mudit Jain billed 1,617 services in 24 codes, and Medicare paid $139K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-12-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 844 | 341 | $94.42 | $80K |
| 95251 Test - Miscellaneous | Office | 156 | 66 | $26.21 | $4,089 |
| 99204 Office E&M - New | Office | 112 | 112 | $121.84 | $14K |
| 99213 Office E&M - Established | Office | 110 | 85 | $63.67 | $7,004 |
| 76536 Ultrasound - Nonspecific | Office | 83 | 76 | $80.65 | $6,694 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 82 | 82 | $122.54 | $10K |
| G0444 Annual depression screening, 5 to 15 minutes | Office | 68 | 68 | $18.80 | $1,278 |
| 99215 Office E&M - Established | Office | 54 | 39 | $132.17 | $7,137 |
| 10005 Other Organ Systems | Office | 27 | 27 | $100.81 | $2,722 |
| 10006 Other Organ Systems | Office | 17 | 14 | $46.55 | $791 |
| 99495 Chronic, Principal, and Transitional Care Management | Office | 11 | 11 | $160.25 | $1,763 |
By year: 2022 $155K for 1,650 services; 2023 $133K for 1,459 services; 2024 $139K for 1,617 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mudit Jain prescribed most often to Medicare patients was Levothyroxine Sodium, with 804 prescriptions and refills. In total Mudit Jain wrote 10,713 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 804 | 2,273 | 279 | $7,846 |
| Ozempic Semaglutide | 701 | 927 | 183 | $855K |
| Metformin Hcl Generic | 693 | 1,945 | 258 | $3,676 |
| Atorvastatin Calcium Generic | 586 | 1,675 | 211 | $4,655 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 478 | 990 | 156 | $53K |
| Jardiance Empagliflozin | 383 | 609 | 115 | $344K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 367 | 891 | 156 | $38K |
| Rosuvastatin Calcium Generic | 365 | 1,053 | 141 | $4,035 |
| Synthroid Levothyroxine Sodium | 291 | 653 | 76 | $25K |
| Farxiga Dapagliflozin Propanediol | 267 | 469 | 75 | $263K |
| Novolog Flexpen Insulin Aspart | 250 | 489 | 98 | $58K |
| Ezetimibe Generic | 248 | 707 | 96 | $3,107 |
| Mounjaro Tirzepatide | 223 | 281 | 56 | $294K |
| Glipizide Generic | 191 | 516 | 65 | $1,188 |
| Trulicity Dulaglutide | 171 | 233 | 38 | $220K |
Brand drugs: 5,024 claims; generic drugs: 5,050 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mudit Jain $13K ($13K in general payments such as food, travel and fees) from 20 companies. The largest payer was Corcept Therapeutics with $11K.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 19 | $11K |
| Medtronic, Inc. MDT | 1 | $550 |
| Novo Nordisk Inc NVO | 9 | $278 |
| Amgen Inc. AMGN | 3 | $93.52 |
| Dexcom, Inc. DXCM | 5 | $89.82 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $84.22 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $68.67 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $60.82 |
| Beta Bionics, Inc. BBNX | 2 | $51.25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $50.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.